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Abstract
Human African trypanosomiasis is a threat to millions of people living in sub-Saharan countries and
is fatal unless treated. At present, the serological and parasitological tests used in the field for
diagnosis of sleeping sickness have low specificity and sensitivity. There is clearly an urgent need for
accurate tools for both diagnosis and staging of the disease. The Foundation for Innovative New
Diagnostics and the World Health Organization have announced that they will collaborate to
develop and evaluate new diagnostic tests for human African trypanosomiasis.
Development of diagnostics for human African 
trypanosomiasis
Background
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is caused by protozoan parasites of the
genus Trypanosoma. Infection with T. brucei gambiense
results in the chronic form of sleeping sickness in West
and Central Africa, whereas T. brucei rhodesiense gives rise
to the acute form of the disease in East and Southern
Africa. If left untreated, the disease is fatal, and therefore
early diagnosis is essential. However, existing diagnostic
tests for HAT are not sensitive and specific enough, and
are difficult to use in rural areas. Therefore, the Founda-
tion for Innovative New Diagnostics (FIND) and the
World Health Organization (WHO) held a joint meeting
in Geneva, Switzerland, on February 6–7, 2006, to launch
a new initiative for the development of new diagnostic
tests to support the control of sleeping sickness. This initi-
ative is funded by a grant of 10 million USD for the next
5 years from the Bill & Melinda Gates Foundation
(BMGF). Representatives from FIND, WHO, BMGF, phar-
maceutical companies, national control programs and the
academic sector attended the meeting to discuss current
problems and necessary improvements in the diagnosis of
HAT.
Over 97% of all sleeping sickness cases reported in the
past 5 years were T. b. gambiense infections (P. Simarro,
personal communication). The common test for serodiag-
nosis of T. b. gambiense sleeping sickness is the Card
Agglutination Test for Trypanosomiasis (CATT) [1]. How-
ever, this test does not detect T. b. rhodesiense. One prob-
lem with the CATT is its low specificity of 74–95% with a
sensitivity of 87–98% [2-4]. Therefore, demonstration of
the parasite in tissue fluids of a patient is strictly required
before the initiation of chemotherapy, especially as some
drugs used for treatment of sleeping sickness have serious
side effects [5]. However, parasitological detection of
trypanosomes in blood sample is often difficult because
of relatively poor sensitivity of microscopic techniques
and of low and fluctuating parasitaemias. Another prob-
lem in HAT diagnosis is the staging of the disease. The
early stage of sleeping sickness is defined by the restriction
of the parasites to the blood and lymph systems. The late
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trypanosomes and an increase white blood cell (WBC)
count in the cerebrospinal fluid (CSF). As there are no
clear clinical criteria for early and late stage disease [6],
staging relies on the examination of the CSF obtained by
lumbar puncture which is painful, risky and complicated
when performed under the field conditions. However, the
number of trypanosomes in the CSF is usually scanty and
WBC counts are variable. In addition, staging based on
WBC counts is not standardised; the suggested cutoff
ranging between 5 WBC/µl to 20 WBC/µl [7]. Hence,
there is a need for new diagnostic tools that are simple and
efficient in the detection of both stages of HAT.
What are the technical options for the development of 
new and improved HAT diagnostics?
One possibility could be the development of an antibody
detection test that uses an antigen different from that of
the CATT (lyophilized T. b. gambiense bloodstream forms
of the variable antigen type LiTat1.3). So far, there are
about 20 potential antigens characterised, available as
recombinant or synthetic polypeptides, which could be
used for a serodiagnostic test for HAT. In addition, a dif-
ferent test format could be employed, e.g. lateral flow or
gel agglutination. Finally, tests could be developed for the
detection of both T. b. gambiense and T. b. rhodesiense.
Development of an antigen detection test seems to be
more difficult; while a test for the detection of circulating
antigens in sleeping sickness patients has been described,
the Card Indirect Agglutination Trypanosomiasis Test
(CIATT) [8], there are some doubts about its specificity
[9]. Nevertheless, other antigens, e.g. secreted enzymes,
could be used in the development of an antigen detection
assay. Another option for the development of new diag-
nostic tests for HAT could be the use of molecular meth-
ods. Although the implementation of PCR methods in the
field is not feasible at the moment, a simplified PCR test
may be possible for field use. The loop-mediated isother-
mal amplification (LAMP) reaction is a simple nucleic
acid amplification (NAA) method that produces large
amounts of target-specific DNA under isothermal condi-
tions with a simple incubator [10]. Another advantage of
the LAMP method is that DNA amplification can be mon-
itored with the naked eye without the use of special detec-
tion devices. Given the extremely limited infrastructure in
the settings in which HAT occurs however, there is still
substantial progress to be made before NAA testing can be
widely implemented as a diagnostic tool for HAT.
The development of tools for staging of HAT is much
more difficult. One option could be a simplified CSF
examination. For instance, tests could be designed that
detect markers for inflammatory reactions of the brain
(e.g. neurological autoantibodies, cytokines, intrathecal
IgM [11,12]) or fragments of trypanosomes or nerve cells
in the CSF, although the latter occurs very late in the infec-
tion. The development of a staging test that does not
require CSF sampling is even harder. One possibility
could be the detection of neurological antigens in the
blood. However, this requires research into the identifica-
tion and characterisation of such antigens in the first
place. Another interesting non-invasive staging method is
polysomnography, the monitoring and recording of phys-
iological data during sleep. It has been shown that late
stage sleeping sickness patients have a disturbed circadian
distribution of the sleep-wake episodes as well as an
altered sleep structure with frequent sleep onset rapid eye
movement periods (SOREMPs) [13]. Importantly, early
evidence suggests that SOREMPs appear soon after the
central nervous system invasion by trypanosomes. How-
ever, polysomnography is a demanding technique which
has to be shown that it can be used routinely under field
conditions.
What are the roles of FIND and WHO in the development 
of new diagnostic tools for HAT?
FIND is an independent and a non-profit foundation
based in Geneva [14]. FIND's activities in this initiative
will be focus on the development, evaluation and demon-
stration of new HAT diagnostics. First, FIND will work in
partnership with academic and industry groups to
develop promising diagnostic assays into applicable prod-
ucts. Next, FIND will establish a formal mechanism to
evaluate these products in field trials. Finally, FIND will
collaborate with WHO, other agencies and national pro-
grammes to demonstrate the impact that use of these
products has on HAT control. In other words, FIND will
create a network of public and private partners to produce
new diagnostic tests for HAT and to demonstrate their
effectiveness. For upstream research discovery and down-
stream implementation activities FIND will liaise with the
relevant partners.
The role of WHO in this initiative is to establish a network
of experienced diagnostic centres in Africa with the capac-
ity to enrol 300 – 500 confirmed sleeping sickness
patients per year and to characterise samples from up to
1000 endemic controls. In addition, the WHO will ensure
that the diagnostic capacity is maintained in study areas
and that national HAT control programmes are fully inte-
grated into the evaluation of the new tests. Furthermore,
the WHO will establish a HAT specimen bank by collect-
ing reference materials from well characterized patients
and controls, assigning a professional facility to be
responsible for cryopreservation, and managing the distri-
bution of specimens to support the development and val-
idation of new tests. Finally, the WHO will provide
training in the application and evaluation of the new diag-
nostics and give operational support to the conduct of
field trials.Page 2 of 3
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FIND and WHO have started a collaboration to develop
urgently needed new diagnostic tools for HAT. The new
tests should ideally be simple (easy to be used by minimal
trained staff in the field), rapid (to be carried out in less
than 30 min), efficient (better than the current diagnos-
tics) and cheap (less than 1 USD per person). It is hoped
that the new tests will allow for early case detection and
simplified staging that will improve disease management
and ultimately support the elimination of sleeping sick-
ness as a public health problem.
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